Teva has advised that supply issues are affecting methylphenidate ER 18 mg, 27 mg, 36 mg and 54 mg tablets.
All strengths are affected by this and the RNZCGP is working with Pharmac around the supply issue with the brand methylphenidate (Teva ER methylphenidate). Pharmac is trying to find alternative brands such as Concerta or Rubifen SR and working with Teva on resupply dates for Teva ER methylphenidate.
Read more on the Pharmac website.
There are a number of pharmaceutical supply issues occurring across New Zealand. The best way a practice can keep an eye on this is through the Pharmac website and you'll find a quick link on our homepage. We encourage practices who are encounter ongoing issues with supply of particular pharmaceuticals to inform us so we can bring this to Pharmac’s attention.
An occasional series illustrating the value of using PowerBI to explore your own data. This issue focuses on 'off label' use of melatonin.
Read moreDue to supply issues, weekly dispensing began occurring from 26 January 2023. This limit is in place until 28 February 2023.
Read moreThis programme provides funding for Aclasta infusions for eligible patients. The infusion is to be provided in the community by the patient’s general practice.
View detailsDr Jo Scott-Jones and Dr Dave Maplesden discuss assessing capacity (in activating enduring power of attorney), HPV screening, changes to opioid prescribing and more.